Low (PP ≤ 5 %) | Moderate (PP 5–40 %) | High (PP > 40 %) | Overall | |
---|---|---|---|---|
Sites | Kilifi (Kenya), Korogwe (Tanzania), Manhiça (Mozambique) | Bagamoyo (Tanzania), Lambarene (Gabon), Agogo (Ghana), Kintampo (Ghana), Lilongwe (Malawi) | Siaya (Kenya), Kombewa (Kenya), Nanoro (Burkina Faso) | |
Control group incidence (95 % CI) of clinical malaria per child per year in each 6–month follow-up period for infants receiving the first vaccine dose at age 6–12 weeks | ||||
0–6 months | na | 0.74 (0.65–0.83) | 2.82 (2.62–3.03) | 1.20 (1.13–1.28) |
6–12 months | 0.13 (0.088–0.185) | 0.96 (0.87–1.06) | 3.69 (3.46–3.93) | 1.54 (1.46–1.62) |
12–18 months | 0.20 (0.14–0.27) | 0.91 (0.82–1.01) | 3.35 (3.13–3.59) | 1.50 (1.42–1.59) |
Control group incidence (95 % CI) of clinical malaria per child per year in each 6–month follow-up period for children receiving the first vaccine dose at age 5–17 months | ||||
0–6 months | 0.058 (0.030–0.101) | 1.10 (1.00–1.19) | 3.32 (3.12–3.53) | 1.56 (1.48–1.64) |
6–12 months | 0.13 (0.09–0.19) | 1.49 (1.39–1.60) | 4.59 (4.35–4.83) | 2.11 (2.02–2.20) |
12–18 months | na | 1.14 (1.04–1.24) | 3.46 (3.25–3.67) | 1.67 (1.59–1.75) |
Incidence of severe malaria per 1000 children (95 % CI) per year across the whole follow-up period | ||||
Infants receiving the first vaccine dose at age 6–12 weeks | 2.51 (0.06–14.10) | 27.2 (17.0–41.1) | 56.3 (41.7–74.5) | 39.0 (27.7–38.4) |
Children receiving the first vaccine dose at age 5–17 months | 4.62 (0.95–13.5) | 39.0 (29.8–50.2) | 61.2 (47.1–78.2) | 39.3 (32.7–46.7) |